Table 2.
Serum α-fetoprotein level of different tumor related factors n (%)
Variables | n = 2304 | AFP (μg/L) | P value |
HBV infection | < 0.001 | ||
Yes | 1875 (81.4) | 573.9 ± 547.7 | |
No | 429 (18.6) | 398.4 ± 522.3 | |
Tumor size(cm) | < 0.001 | ||
≤ 5 | 871 (37.8) | 444.9 ± 514.2 | |
5-10 | 804 (34.9) | 499.5 ± 536.4 | |
≥ 10 | 629 (27.3) | 808.4 ± 529.2 | |
Tumor number | 0.451 | ||
1 | 1666 (72.2) | 531.9 ± 18.9 | |
2 | 288 (12.5) | 532.2 ± 44.7 | |
≥ 3 | 350 (15.3) | 556.0 ± 42.2 | |
Vascular invasion | < 0.001 | ||
No | 1714 (74.4) | 502.1 ± 543.1 | |
Yes | 590 (25.6) | 694.1 ± 546.9 | |
Tumor differentiation1 | 0.007 | ||
High | 139 (7.5) | 207.3 ± 420.8 | |
Intermediateb | 963 (52.3) | 527.9 ± 538.4 | |
Low | 741 (40.2) | 559.2 ± 545.7 | |
TNM staging | 0.306 | ||
I | 495 (21.5) | 578.6 ± 549.3 | |
II | 289 (12.5) | 493.3 ± 542.2 | |
IIIA | 726 (31.5) | 548.6 ± 544.3 | |
IIIB | 214 (9.3) | 585.3 ± 553.4 | |
IIIC | 101 (4.3) | 558.9 ± 551.7 | |
IV | 479 (20.8) | 534.0 ± 545.9 | |
BCLC staging | 0.008 | ||
A | 869 (37.7) | 506.2 ± 537.4 | |
B | 251 (10.9) | 590.1 ± 551.1 | |
C | 1028 (44.6) | 607.3 ± 553.3 | |
Dd | 156 (6.8) | 625.7 ± 529.8 | |
China staging | 0.386 | ||
I | 137 (5.9) | 487.8 ± 542.2 | |
IIa | 198 (8.6) | 528.8 ± 533.9 | |
IIb | 893 (38.7) | 560.8 ± 545.7 | |
III | 1076 (46.7) | 527.9 ± 544.8 |
We assessed 1843/2304 patients who had underwent hepatectomy or fine needle aspiration.
P < 0.001 vs high and low differentiation groups.
P < 0.001 vs stage A and B of BCLC. AFP: α-fetoprotein; HBV: Hepatitis B virus; TNM: Tumor-node-metastasis; BCLC: The Barcelona-Clinic Liver Cancer Group.